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Abstract 
We conducted a systematic literature review to explore the association between circulating C-reactive protein 
(CRP), a low-grade inflammation biomarker, and breast cancer risk. Relevant prospective studies in women 
were identified in PubMed and Web of Science until February 2015. Random-effects dose-response meta-
analysis was conducted, overall and in post-menopausal women. Twelve out of 15 studies identified were 
included in the meta-analysis on any breast cancers (3,522 cases, 69,610 women) and nine on post-
menopausal breast cancer (2,516 cases, 36,847 women). For each doubling of CRP concentration, a 7% 
(95% CI: 2%–12%) and 6% (95% CI: 1%–11%) increased risk was observed (I2=47% and 32%; P 
heterogeneity=0.04 and 0.17), respectively. The association was linear over most of the range of CRP 
concentrations. Positive associations remained in the studies that examined the exclusion of early years of 
follow-up. Associations were attenuated in studies adjusted for lifestyle factors, which partly explained the 
significant heterogeneity between studies in the overall analysis. On average, the associations in studies 
adjusted or not adjusted for body mass index were similar.  
Low-grade inflammation may have a role in breast cancer development. Additional prospective studies are 
needed to better understand confounding and effect modification from lifestyle factors.  
 
(198 words) 
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Introduction 
Several studies have explored the intricate association between chronic inflammation and cancer, but 
whether chronic inflammation has a causal role in cancer pathogenesis, or is simply a marker of the disease 
is unclear. Indeed, some cancers arise at sites of chronic inflammation, while other cancers induce an 
inflammatory microenvironment (1). C-reactive protein (CRP) is a sensitive, non-specific biomarker of 
inflammation that is produced in the liver. Circulating CRP level is acutely elevated in response to 
proinflammatory cytokines (tumour necrosis factor-alpha, interleukin-6) following an infection or tissue 
damage, and moderately elevated in the state of low-grade inflammation (1). High-sensitive assay methods 
with detection limits of <0.3 mg/L can readily measure lower concentrations of CRP in blood (2). 
CRP levels have been shown to increase with obesity (3), smoking (4), post-menopausal hormone use (5), 
and to be lower with higher physical activity levels (6), better diet quality (7), and higher alcohol intake (8). 
Obesity-induced inflammation is associated with upregulation of proinflammatory cytokines, which promote 
neoplasia and tumour progression (9). Chronic inflammation is also linked directly to tumour initiation and 
promotion, through the production of reactive oxygen species and reactive nitrogen species that induce 
genomic instability and DNA damage (10).        
Increased concentration of CRP is associated with increased risk of cardiovascular diseases and mortality 
(11), colorectal cancer (12) and lung cancer (13). Poorer prognosis in cancer patients, including those of 
breast cancer was also reported (1, 14), but evidence on the association of CRP with breast cancer risk is 
inconsistent. The association may also differ by degree of body adiposity. Stronger positive associations in 
overweight and obese women than in normal weight women were reported by a recent hospital-based case-
control study (15), although reverse causation (inflammatory processes induced by occult cancer) could 
have influenced the results in this study.  
In 2013, a meta-analysis of six prospective studies reported a non-significant positive association of CRP 
concentration and breast cancer risk, with moderate heterogeneity between studies (16). Since then, six 
more large-scale prospective studies (17-22) [three American (18-20), two French (17, 21), and one Chinese 
(22) studies] have been published, adding 2,038 cases and 27,968 study participants to the evidence. 
Hence, we conducted an updated systematic review and meta-analysis to investigate whether circulating 
CRP, a biomarker of chronic inflammation, is a risk factor for breast cancer development. We based the 
review on prospective studies because in these studies blood samples were collected before breast cancer 
diagnosis. We further examined the association in relation to possible biases from reverse causation, 
confounding, and effect modification by body adiposity.   
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Materials and Methods 
A PRISMA checklist (23) of the items reported in this review is provided in Supplementary Methods and 
Materials 1.  
Data sources and search  
We searched systematically in PubMed and Web of Science (databases: MEDLINE, Web of Science Core 
Collection, CAB Abstracts, Current Contents Connect, and Journal Citation Reports) for articles on 
circulating CRP and breast cancer in humans, that were published on any language from database inception 
to February 2015. The search strategy contained medical subject headings and/or variants of text words on 
CRP and breast cancer (Supplementary Methods and Materials 2). We also hand-searched the reference 
lists of relevant articles and reviews. 
Study selection 
Prospective studies (cohorts, follow-up of participants in randomised controlled trials, case-control nested 
within a cohort, and case-cohort) that reported a measure of association between pre-diagnosis circulating 
CRP concentrations in blood and subsequent risk of breast cancer development in women were selected. 
Abstract review and selection was conducted in duplicate (DSMC, TN).  
Data extraction 
Study and population characteristics, biomarker assessment methods and sample type, CRP concentrations, 
number of breast cancer cases and population at-risk, and all relative risk (RR) estimates (hazard ratios and 
odds ratios) and the corresponding 95% confidence intervals (CI) or P-values, matching factors, confounder 
adjustments, and effect modifiers used in the studies were extracted. 
Statistical analysis 
Fixed-effect and random-effects dose-response meta-analyses were conducted. As there was evidence of 
heterogeneity between studies, only results from random-effects model that allows for possible variations of 
associations across the studies were reported. We used DerSimonian and Laird’s method (24) to calculate 
the weighted average of the natural logarithm (ln) of the RRs of each study, and back-transformed using the 
exponential function. CRP was natural log-transformed to normalise data for analysis. The increment unit of 
the meta-analysis was per doubling (100% increase) of CRP concentration. For studies that reported a dose-
response slope per doubling of CRP concentration, we used the result directly. For studies that reported a 
dose-response slope per 1 ln unit increase, we re-scaled the result to per doubling of CRP concentration by 
raising the RR and 95% CI to the power of 0.693 [In(2)]. For studies that only reported categorical data, we 
estimated the study-specific slope using generalised weighted least-squares regression model (25) based on 
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the method of Greenland and Longnecker (26). In this method, adjusted log RRs are regressed on the 
exposure doses across the categories in a study, taking into account the correlation between risk estimates 
that are calculated using a common reference group. The method requires that the numbers of breast cancer 
cases and population at-risk for at least three categories of CRP concentrations and their means or medians 
values are provided. When the ranges of each category of CRP concentrations were instead reported, we 
assigned the corresponding RR to the midpoints of the category range. When the highest category was 
open-ended, we estimated the range using the width of the adjacent category. When the lowest category 
was open-ended, we used 0.1 mg/L as the lowermost concentration. Studies without the required data for 
the procedures were excluded from the analysis. 
Maximally adjusted RRs reported in the papers were used in the meta-analyses. To assess heterogeneity 
between studies, we calculated the Cochran Q test (Ph) and I2 statistic (%) (27). Sources of heterogeneity 
were explored in subgroups defined by number of cases, length of follow-up, publication year, study design, 
geographic location, CRP assessment method, and adjustments for confounders. To examine possible 
reverse causation, we restricted the studies into three groups based on exclusions of early years of follow-up 
as defined by the studies–studies with no exclusion of early years of follow-up; studies that reported a 
measure of association after the exclusion; and studies that reported no appreciably change of the estimates 
after the exclusion but did not show the results.  
Egger’s test and visual inspection of the funnel plot were performed to examine small study or publication 
bias (28). Each individual study was omitted in turn to examine the influence on the summary RR.  
Furthermore, we examined the shape of the association using second order fractional polynomial models 
(29), including the studies with three or more categorical results and the required data for slope estimation as 
mentioned above. The fractional polynomial regression model with the lowest deviance was the best fitting 
model. Non-linearity was tested using the likelihood ratio test (30).  
P<0.05 was considered statistically significant in all analysis, except for Egger’s test, where P<0.10 was 
used because of the low power of the test. All analyses were conducted using Stata version 12.0 (StataCorp. 
2005. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP). 
 
Results 
Results of search 
Fifteen studies (16 publications) (17-22, 31-40) on CRP concentrations and breast cancer risk were identified 
in the literature search. Figure 1 shows the flowchart of search. Three studies (32, 36, 37) did not provide 
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sufficient information to estimate a RR for each doubling of CRP concentration and could not be included in 
the meta-analysis (Supplementary Table S1). One study (32) reported a non-significant positive association 
when comparing CRP 6.5 with 0.4 mg/L. The result was attenuated with adjustment for BMI.  Another study 
(36) reported a non-significant positive association per 3.2 mg/L increase of CRP concentration. BMI was 
accounted for in the study. The third study (37) reported a non-significant inverse association when 
comparing CRP ≥50.0 with <10 mg/L. The referent category in this study included low-grade inflammation, 
and may have resulted in an underestimation of the association between CRP and breast cancer 
(Supplementary Table S1). Hence, 12 studies (17-22, 31, 33-35, 38, 39) (3,522 cases, 69,610 women) were 
included in the dose-response meta-analysis of all studies (any breast cancers) and nine studies (17-19, 22, 
33-35, 38, 40) (2,516 cases, 36,847 women) in the meta-analysis of post-menopausal breast cancer. Meta-
analysis of pre-menopausal breast cancer was not conducted as only two studies (22, 40) reported results 
(Table 1). For the highest compared with the lowest CRP concentrations, one study (40) reported a non-
significant inverse association and the other study (22) reported a significant positive association with pre-
menopausal breast cancer. 
Study characteristics 
Table 1 shows the characteristics and results of the prospective studies included in the present meta-
analysis. There were one Asian study (22), five European studies (17, 21, 31, 33, 35), and six American 
studies (18-20, 34, 38, 39). In some studies, hormone therapy (HT) users (18), women with cardiovascular 
diseases (39) or liver cirrhosis (31) were excluded. Ollberding et al. (19) was a multi-ethnic cohort and 
Prizment et al. (20) was of white women only. Five studies (6 publications) consisted of pre- and 
postmenopausal women (20-22, 31, 39, 40), of which only two studies further reported results by age groups 
(22) or menopausal status (40). Seven studies were of post-menopausal women only (17-19, 38), or in 
women aged ≥55 years (33-35).  
The number of breast cancer cases ranged from 33 cases (34) to 892 cases (39). The study follow-up 
ranged from an average of 4.9 years (22) to 13 years (31) . Concentrations of CRP varied between studies, 
with the highest categories ranging from <0.28 to ≥0.72 mg/L (38) to 0.1–1.1 to 2.7–28.6 mg/L (18).     
Studies controlled for multiple risk factors (reproductive and lifestyle factors but no dietary factors) for breast 
cancer through matching or adjustment in the statistical models that were determined a priori or by whether 
its inclusion in the model changed the risk estimate significantly. Three studies (21, 22, 39) adjusted for BMI, 
alcohol consumption, physical activity, and smoking simultaneously. Two studies (20, 33) also adjusted for 
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non-steroidal anti-inflammatory drug (NSAID) use and three studies (20, 21, 33) adjusted for socioeconomic 
status.  
Overall dose-response meta-analysis 
Table 2 is a summary of the results from the dose-response meta-analyses. The studies included in each 
stratified analysis are listed in Supplementary Table S2. 
Circulating CRP was statistically significantly positively associated with breast cancer risk (Table 2, Fig. 2). 
The summary RR per doubling of CRP concentration was 1.07 (95% CI: 1.02–1.12). There was evidence of 
significant heterogeneity between studies (I2 = 47%, Ph = 0.04), which was partially explained by level of 
control for confounders. Studies that did not adjust for HT use, physical activity, or alcohol use reported on 
average stronger associations than studies adjusted for these factors. Positive associations although not 
always statistically significant were observed in most stratified analyses, with the exception of analyses 
restricted to studies that adjusted for physical activity and alcohol use. In the subgroup analyses by the 
exclusion of early years of follow-up in the studies, the summary RRs were significant  in studies without the 
exclusion, slightly weaker in studies that reported no change in the estimates after the exclusion, and non-
significant in studies with the exclusion. Summary estimates were of similar magnitude for studies that 
adjusted and not adjust for BMI (Table 2).  
Dose-response meta-analysis for post-menopausal breast cancer                  
For post-menopausal breast cancer, the summary RR per doubling of CRP concentration was 1.06 (95% CI: 
1.01–1.11) when all nine studies (17-19, 22, 33-35, 38, 40)  were combined (Table 2, Fig. 2). There was 
evidence of moderate heterogeneity between studies (I2 = 32%, Ph = 0.17), which was mostly explained by 
the Women’s Health Study (WHS) (40) which had the biggest contribution (22% weight) in the analysis. 
When the study was excluded, the summary RR was 1.08 (95% CI: 1.04-1.13) and I2 reduced to 0% (Ph = 
0.52). The WHS was a follow-up of a randomised controlled trial evaluating the benefits and risks of low-
dose aspirin and vitamin E in the primary prevention of cancer and cardiovascular disease in US female 
health professionals (39, 40).  
The significant positive association persisted in studies that excluded early years of follow-up, or reported no 
change of estimates after the exclusion. Similar positive associations were observed in the meta-analyses of 
studies that were adjusted or not adjusted for BMI (Table 2). The summary RRs were 1.08 (95% CI: 1.03–
1.13) for four studies not adjusted for BMI (17-19, 34) and 1.06 (95% CI: 1.00–1.12) for seven studies 
adjusted for BMI (18, 19, 22, 33, 35, 38, 40). Moderate heterogeneity was only observed between studies 
that were adjusted for BMI (Not adjusted: I2 = 0%, Ph = 0.64; Adjusted: I2 = 40%, Ph = 0.13). Only two studies 
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(18, 19), both of post-menopausal women only, reported results for both models; when the two studies were 
combined, the summary RR was 1.07, 95% CI: 1.01–1.13 before adjustment for BMI and 1.06, 95% CI: 
0.99–1.12 after adjustment (results not tabulated). As in the meta-analysis for overall breast cancer, no 
associations were observed in studies that adjusted for physical activity and alcohol use (Table 2).  
Three studies with data on postmenopausal women (17, 19, 40)  investigated whether the association 
between circulating CRP and breast cancer risk varies according to BMI, and reported inconsistent results 
(Table 1). One study (17) reported a significant positive association of CRP with breast cancer among 
women with BMI ≥ 25 kg/m2, whereas another study (40) reported an inverse association for the same BMI 
group. The third study (19) reported an association close to null among women with BMI ≥ 30 kg/m2, but non-
significant positive associations in women with BMI <25 or between 25–29.9 kg/m2 (all P ≤0.03 for interaction 
or heterogeneity).           
Other sensitivity analysis and test of publication bias 
The summary RRs remained similar when each study was omitted in influence analyses including all studies 
or studies of post-menopausal women. Egger’s tests showed some evidence of publication or small study 
bias (Overall: P = 0.08; Post-menopausal: P = 0.10). Visual inspection of the funnel plots showed that small 
studies with a null or weaker association than the average may be missing (Supplementary Fig. S1). 
Non-linear dose-response meta-analysis 
In the analysis of all studies (any breast cancers), although the test for departure from linearity was 
statistically significant, the shape of the association was linear over most of the CRP range on the 
logarithmic scale [Pnon-linearity = 0.01; 10 studies (17-22, 31, 35, 38, 39)] (Fig. 3). In post-menopausal women, 
the increase in risk was sharper and tailed off after 4 mg/L [Pnon-linearity < 0.001; 7 studies (17-19, 22, 35, 38, 
40)], probably because of the low number of points contributing to the analysis after this value, resulting in 
wide confidence intervals. 
 
Discussion 
By combining the current evidence from prospective studies of circulating CRP, a systemic low-grade 
inflammation biomarker, and breast cancer risk, 3,522 breast cancer cases and 2,516 post-menopausal 
breast cancer cases could be included in meta-analyses. Overall, we found a modest statistically significant 
positive association. For each doubling (100% increase) of CRP concentration, there was a 7% increase in 
breast cancer risk and a 6% increase in post-menopausal breast cancer risk. The relationship was linear on 
the logarithmic scale. The observed association with circulating CRP was also present in studies that 
9 
 
examined reverse causation by excluding cases diagnosed in early years of follow-up. Our meta-analysis is 
consistent with a recently published meta-analysis that showed an inverse negative association between 
NSAIDs use and breast cancer risk (summary RR = 0.97, 95% CI: 0.94–1.00; I2 = 88%, Ph <0.001; 12 cohort 
studies) (41). However, the few studies that examined genotypes that influence CRP levels in blood and 
breast cancer risk did not offer consistent results (20, 42-45). The elevated CRP could be a marker of host 
response to early malignancy or disease progression instead of a causal factor for breast cancer 
development. Our results therefore need to be confirmed in future studies. 
A number of limitations should be considered when interpreting our findings. Seven out of 12 studies 
included in the overall analysis were of post-menopausal women only (17-19, 33-35, 38). Thus pre-
menopausal women were underrepresented in the present review. Significant heterogeneity existed in the 
overall meta-analysis. Differences in the level of control for confounding in the studies may partly explain the 
heterogeneity, but the evidence provided by the meta-analysis is limited by the low number of studies in the 
subgroup analyses. Also, the studies included in the subgroups are different, which hinder direct 
comparisons between the results. On average, the associations in studies that were unadjusted for HT use, 
physical activity, or alcohol use appeared stronger compared with adjusted results. Similar significant 
associations were observed in the studies adjusted or not adjusted for BMI. However, direct comparison was 
only possible in two studies of post-menopausal women that reported multivariable results from both models 
adjusted and not adjusted for BMI (18, 19), and the results were slightly attenuated after adjustment for BMI. 
The association could also be mediated or modified by body adiposity, but the data were limited and 
equivocal (17, 19, 40).  
Another limitation is that some studies could not be included in the meta-analyses because of insufficient 
data (32, 36, 37). If included, the summary association would have been weakened by one large study 
(1,241 cases) (37) which reported a possibly underestimated (non-significant inverse) association of CRP 
that was detected by a conventional assay. Other excluded studies (32, 36) reported results similar to those 
included in the meta-analysis. Funnel plots showed that small studies with a null or weaker association than 
the average estimated in this meta-analysis may be missing. However, as our search included the major 
sources for searching related literature [MEDLINE using the platform of PubMed and the reference lists of 
related publications (46)], it is unlikely that we missed publications in our review.  
Although CRP concentrations have good consistency over time (47, 48), the studies included in the review 
only performed one CRP assessment at study baseline and some misclassification cannot be excluded, 
possibly leading to attenuation of association.     
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Taken together, evidence suggested a role of chronic inflammation in breast cancer development. Breast 
cancer risk increases with increasing CRP concentration in a dose-response manner. Possible confounding 
and modifying effect of obesity and other lifestyle factors and the mechanisms underlying the association 
warrants further investigation. 
Words: 3,061 words      
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Table 1. Characteristics and results of studies included in the dose-response meta-analysis of circulating CRP and breast cancer risk 
Author, Year Study, 
Country 
Study design 
Assessment period 
Follow-up length 
 
Study size and 
cases 
Participant 
characteristics 
CRP assessment 
 
Biomarkers 
comparison 
Results Adjustments or matching 
factors 
Wang et al., 2015 
(22)  
CKFC, China 
PC, 73.9% response  
2006–2007  
Average 4.9 y 
19,437 women, 87 
cases  
Mean age 49.2 y 
10,130 women <50 y 
9,307 women ≥50 y 
High-sensitivity 
nephelometry assay 
Fasting sample 
Plasma hs-CRP 
>3.0 vs. <1 mg/L 
 
 
 
 
 
 
 
>3.0–≤10 vs. <1 
mg/L 
Overall: 
1.74 (1.01–2.97) 
P trend = 0.05 
<50 years: 
2.76 (1.18–6.48) 
≥50 years: 
1.34 (0.68–2.64) 
 
Overall: 
1.89 (1.08–3.32) 
P trend = 0.03 
Age, BMI, smoking, drinking, 
diabetes, physical activity, 
marital status 
Dossus et al., 2014 
(17)  
E3N study, France 
NCC  
1995–1999  
Maximum 10 y  
549 cases, 1,040 
controls 
Mean age 57.6 y 
Post-menopausal 
Immuno-turbidometric 
assay Average 4.2 y < 
diagnosis 
Non-fasting sample 
CRP ≥ 10 mg/L 
excluded 
Serum hs-CRP 
2.5–<10.0 vs. <1.5 
mg/L 
 
 
 
 
 
 
Per 1 natural log-
unit 
Post-menopausal: 
1.24 (0.92–1.66) 
 
BMI<25 kg/m2: 
0.93 (0.61-1.41) 
BMI ≥25 kg/m2: 
1.92 (1.20-3.08) 
P interaction = 0.03 
 
1.13 (0.98–1.29) 
Age, menopausal status, date 
and centre at blood collection, 
age at menopause. a 
 
Gaudet et al. 2013 
(18)  
CPS-II Nutrition 
Cohort, USA 
NCC  
1998–2001 
Maximum 9 y 
17 women lost to 
follow-up  
302 cases, 302 
controls  
Age ~65–75 y 
Post-menopausal 
HT non-users  
ELISA-based assays 
Non-fasting sample 
CRP ≥40 mg/L 
excluded 
 
 
 
Plasma CRP 
>2.7–28.6 vs. 0.1–
1.1 mg/L 
 
 
 
Post-menopausal: 
1.19 (0.79–1.79) 
P trend = 0.10 
 
 
 
1.09 (0.70–1.70) 
P trend = 0.16 
Age, time from last meal to blood 
draw, alcohol in 24 hours before 
blood draw, prior diagnosis of 
diabetes, family history of breast 
cancer; race. b 
 
Above factors + BMI 
Ollberding et al., 2013 
(19)  
MEC, USA 
NCC  
2001–2006 
Maximum 8 y 
706 case, 706 
controls  
Mean age 67.8 y 
Post-menopausal 
Multi-ethnic 
Latex-enhanced 
turbidimetric 
measurement   
1–5 y < diagnosis 
Fasting sample 
Serum CRP: 
>4.0 vs. ≤0.9 mg/L 
 
 
 
 
Post-menopausal: 
1.41 (1.01–1.96) 
P trend = 0.014 
 
 
1.33 (0.95–1.87) 
 
BMI<25 kg/m2: 
1.26 (0.75-2.12) 
BMI 25-29.9 kg/m2: 
Ethnicity, location, birth year, 
date and time of blood drawn, 
hours fasting before blood 
drawn, HRT use. c  
 
 Above factors + BMI 
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1.70 (0.94-3.06) 
BMI ≥30 kg/m2: 
1.02 (0.41-2.54) 
P heterogeneity = 
0.008 
Prizment et al., 2013 
(20) 
ARIC, USA 
PC, 81% response  
1996–1998 
35,888 person-years  
4009 women, 176 
cases 
Mean age 62.8 y 
White 
92.0 % post-
menopausal 
Immuno-turbidimetric 
assay 
Plasma hs-CRP: 
≥5.65 vs. ≤1.08 
mg/L 
 
Per 1 natural log-
unit 
 
1.74 (1.00–3.03) 
 
 
1.27 (1.07–1.51)  
 
Excluded <2 years 
follow-up: 
1.40 (1.16–1.70) 
Age, BMI, waist, study center, 
education, aspirin use, smoking 
status, pack-years of smoking, 
HT use, menopausal status, age 
at menarche, number of live 
births 
Touvier et al., 2013 
(21) 
SUVIMAX, France 
NCC from a RCT of 
antioxidant 
supplement  
1994–1995  
Maximum 8 y 
218 cases, 436 
controls 
Mean age 49.2 y 
(cases), 51.5 y 
(controls) 
ELISA  
Fasting sample 
Plasma hs-CRP: 
≥2.0 vs. ≤0.5 mg/L 
 
 
 
 
1.25 (0.73–2.14) 
P trend = 0.70 
 
Age, BMI, height, intervention 
group, alcohol intake, physical 
activity, smoking status, 
educational level 
Allin et al., 2009 (31) 
CCHS, Denmark 
PC 
1991–1994 (61.2% 
response) 
2001–2003 (49.5% 
response)  
Average 13 y 
100% follow-up 
5369 women, 207 
cases  
Age ~44–63 y  
68.4% post-
menopausal Liver 
cirrhosis excluded 
Turbidimetry or 
nephelometry 
Plasma hs-CRP 
≥3.1 vs. ≤0.9 mg/L 
 
 
0.70 (0.40–1.40) 
P trend = 0.40 
 
Age, BMI, smoking, alcohol 
consumption, OC use, 
menopausal status, HT use 
Heikkila et al., 2009 
(33) 
BWHHS, UK 
PC 
1999–2001 
Maximum 7 y 
3274 women, 48 
cases  
Age 60–79 y 
 
Ultrasensitive 
nephelometric assay  
 
hs-CRP 
Per 1 natural log 
unit 
Post-menopausal: 
1.00 (0.76–1.31) 
Age, BMI, smoking, childhood 
and adult socioeconomic 
position, physical activity, HT 
use, NSAID use 
Zeleniuch-Jacquotte 
et al., 2008 (38) 
NYUWHS, USA 
NCC 
6 m–5.5 y  before 
diagnosis (probably 
breast cancer 
already developed) 
85 cases, 163 
controls 
Post-menopausal  
Behring NA latex test 
(nephelometry) 
 
Serum CRP: 
≥0.72 vs. <0.28 
mg/L 
 
Per doubling of 
CRP 
Post-menopausal: 
2.43 (1.09–5.43) 
 
 
1.25 (0.96–1.64) 
Age, date of enrolment, and BMI 
 
 
Zhang et al., 2007 
(39)  
WHS, USA  
 
 
 
 
 
 
PC from a RCT of 
aspirin and vitamin E 
1992 
Average 10.1 y 
97.2%-99.4% follow-
up 
27919 women, 892 
cases 
Age ~52.8–55.5 y  
12, 600 pre-
menopausal women 
15, 318 post-
menopausal women 
Cardiovascular 
diseases excluded 
Latex-enhanced 
immunoturbidimetry 
Plasma CRP: 
≥5.18 vs. ≤0.64 
mg/L 
 
 
 
 
3.1-10 vs. <1 mg/L 
 
Overall: 
0.90 (0.71–1.16) 
Excluded <2 years 
follow-up: 
0.96 (0.73–1.25) 
 
Overall:  
1.02 (0.84–1.24) 
 
Age, BMI, randomised treatment 
assignment, age at menarche, 
age at first pregnancy lasting 6 m 
or longer, number of pregnancies 
lasting 6 mo or longer, 
menopausal status, age at 
menopause, HT use, family 
history of breast cancer in 
mother or a sister, history of 
16 
 
 
 
 
 
 
 
 
Zhang et al., 2008 
(40) 
 Per 1 natural log 
unit 
 
 
 
 
 
 
≥5.18 vs. ≤0.64 
mg/L 
 
1.00 (0.94–1.07)  
BMI ≥25 kg/m2: 
Statistically significant 
inverse association 
P interaction = 0.02 
(data not shown) 
 
Pre-menopausal: 
0.81 (0.46–1.42) 
BMI ≥25 kg/m2: 
P interaction = 0.24 
(data not shown) 
 
Post-menopausal: 
0.90 (0.66–1.23) 
BMI <25 kg/m2: 
Non-significant 
positive association  
P trend= 0.81 
BMI ≥25 kg/m2: 
Significant inverse 
association 
P trend= 0.04 
P interaction = 0.06 
(data not shown) 
benign breast disease, physical 
activity, multivitamin supplement 
use, smoking status, alcohol 
intake 
Siemes et al., 2006 
(35) 
Rotterdam Study, The 
Netherlands 
PC, 89% response 
1989–1993 
Average 10.2 y  
3790 women, 184 
cases 
Age ≥55 y 
 
Near-infrared particle 
immunoassay 
CRP > 10 mg/L 
excluded 
Non-fasting sample 
 
 
Serum hs-CRP: 
3.0-10.0 vs. <1.0 
mg/L 
 
 
 
Per 1 natural log 
unit 
Post-menopausal: 
1.59 (1.05–2.41) 
Follow-up >5 years: 
1.48 (0.94-2.33) 
 
Post-menopausal: 
1.28 (1.07–1.54) 
Follow-up >5 years: 
1.23 (1.02–1.50) 
Age, BMI, smoking, age at 
menarche and menopause, 
hormone use, number of 
children. d 
 
 
 
Il’yasova et al., 2005 
(34)  
HABCS, USA 
PC  
1997–1998 
Average 5.5 y 
1305 women, 33 
cases (mortality 
included) 
Age 70-79 y 
Black and White 
ELISA 
Fasting sample 
Serum hs-CRP 
Per 1 natural log 
unit 
 
 
Post-menopausal:  
1.32 (0.91-1.93) 
 
 
Age, race, study site. e 
a Dossus et al., 2014: HT use, OC use, fasting sample status, smoking status, BMI, waist circumference, waist-to-hip ratio, education level, diabetes, physical 
activity, alcohol consumption, and other factors were tested but not included in the final model as none affected RRs by more than 10%. 
b Gaudet et al., 2013: Former use of HT, OC use, alcohol consumption, and other factors tested but not included in final model.  
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c Ollberding et al., 2013: OC use, alcohol consumption, physical activity, pack-years of cigarette smoking and other factors tested but not included in final model 
as none affected RRs by more than 10%. 
d Siemes et al., 2006: Only significant or well-known covariates were adjusted. 
e Il’yasova et al., 2005: BMI, visceral adiposity, smoking, physical activity, NSAID use, education, medical conditions, and other factors did not materially change 
the associations. 
Abbreviations: ARIC-Atherosclerosis Risk in Communities study, BWHHS-British Women’s Heart and Health Study, CCHS-Copenhagen City Heart Study, CKFC-
Chinese Kailuan Female Cohort, CPS-Cancer Prevention Study, E3N-Etude Epidémiologique auprès de femmes de l'Education Nationale, ELISA-enzyme-linked 
immunosorbent assay, HABCS-Health Aging and Body Composition Study, MEC-Multiethnic Cohort study, NCC-nested case-control study, NYUWHS-New York 
University Women’s Health Study, OC-oral contraceptive, PC-prospective cohort study, RCT-randomised controlled trial, SES-socioeconomic status, SUVIMAX-
The Supplémentation en Vitamines et Minéraux Antioxydants study, WHS-Women’s Health Study 
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Table 2 Summary of dose-response meta-analyses of circulating CRP and breast cancer risk overall 
and in post-menopausal women 
 All studies Post-menopausal women studies 
 Study Cases RR (95% CI) I2 (%), Ph Study Cases RR (95% CI) I2 (%), Ph
           Per doubling of CRP              Per doubling of CRP 
Overall 12 3522 1.07 (1.02-1.12) 47, 0.04 9 2516 1.06 (1.01-1.11) 32, 0.17 
Early years of follow-up  
Excluded 
No changef  
Not excluded  
3 
7 
5 
<1088 
<2098 
1424 
1.13 (0.98-1.30) 
1.05 (1.00-1.10) 
1.12 (1.02-1.24) 
81, 0.006 
0, 0.43 
73, 0.005 
1 
5 
4 
158 
<1632 
883 
1.15 (1.01-1.32) 
1.06 (1.02-1.12) 
1.09 (0.97-1.22) 
- 
0, 0.64 
65, 0.03 
Length of FU 
< 10 years 
≥ 10 years 
 
8 
4 
 
1650 
1872 
 
1.08 (1.04-1.13) 
1.04 (0.96-1.14) 
 
1, 0.42 
70, 0.02 
 
6 
3 
 
1226 
1290 
 
1.06 (1.01-1.12) 
1.07 (0.97-1.19) 
 
0, 0.59 
74, 0.02 
Location 
Asia 
Europe 
North America 
 
1 
5 
6 
 
87 
1246 
2189 
 
1.13 (1.00-1.29) 
1.05 (0.97-1.14) 
1.07 (1.00-1.14) 
 
- 
46, 0.12 
56, 0.04 
 
1 
3 
5 
 
57 
781 
1678 
 
1.07 (0.91-1.26) 
1.10 (1.02-1.20) 
1.05 (0.98-1.11) 
 
- 
17, 0.30 
40, 0.15 
Study design 
NCC 
PC 
 
5 
7 
 
1855 
1667 
 
1.07 (1.02-1.12) 
1.08 (0.99-1.17) 
 
0, 0.60 
66, 0.008 
 
4 
5 
 
1637 
879 
 
1.07 (1.02-1.12) 
1.07 (0.97-1.17) 
 
0, 0.47 
52, 0.08 
Number of cases 
<500 
≥500 
 
9 
3 
 
1375 
2147 
 
1.09 (1.02-1.16) 
1.04 (0.98-1.11) 
 
42, 0.09 
55, 0.11 
 
6 
3 
 
704 
1812 
 
1.09 (1.01-1.17) 
1.04 (0.98-1.12) 
 
19, 0.29 
54, 0.12 
Publication year 
<2010 
≥2010 
 
6 
6 
 
1489 
2033 
 
1.06 (0.97-1.16) 
1.08 (1.04-1.13) 
 
59, 0.03 
0, 0.47 
 
5 
4 
 
907 
1609 
 
1.09 (0.98-1.22) 
1.07 (1.02-1.12) 
 
60, 0.04 
0, 0.76 
CRP assay 
ELISA 
Other assays 
 
3 
9 
 
548 
2974 
 
1.04 (0.96-1.12) 
1.08 (1.02-1.14) 
 
0, 0.47 
59, 0.01 
 
2 
7 
 
330 
2186 
 
1.06 (0.92-1.23) 
1.07 (1.01-1.13) 
 
34, 0.22 
40, 0.12 
Blood sampleg 
Plasma 
Serum 
 
6 
5 
 
1917 
1557 
 
1.04 (0.98-1.11) 
1.11 (1.05-1.17) 
 
55, 0.05 
0, 0.57 
 
3 
5 
 
911 
1557 
 
1.00 (0.95-1.06) 
1.11 (1.05-1.17) 
 
0, 0.60 
0, 0.57 
Fasting statusg 
Fasting 
Non-fasting 
 
4 
3 
 
1044 
1030 
 
1.09 (1.03-1.15) 
1.09 (1.00-1.18) 
 
0, 0.65 
45, 0.16 
 
3 
3 
 
796 
1030 
 
1.09 (1.02-1.16) 
1.09 (1.00-1.18) 
 
0, 0.69 
45, 0.16 
Acute inflammation 
      Not excluded 
Excluded 
     9 
4 
   2492 
1110 
  1.06 (1.00-1.13) 
1.10 (1.03-1.17) 
   50, 0.04 
33, 0.22 
     6 
3 
   1486 
1030 
  1.05 (0.99-1.12) 
1.09 (1.00-1.18) 
  28, 0.23 
45, 0.16 
Confounder adjustments 
BMI 
      No 
      Yes 
4 
10 
1585 
2940 
1.08 (1.03-1.13) 
1.06 (1.01-1.12) 
0, 0.64 
53, 0.03 
4 
7 
1585 
1934 
1.08 (1.03-1.13) 
1.06 (1.00-1.12) 
0, 0.64 
40, 0.13 
Smoking 
No 
Yes 
 
5 
7 
 
1670 
1852 
 
1.07 (1.02-1.13) 
1.06 (0.99-1.14) 
 
0, 0.50 
63, 0.01 
 
5 
4 
 
1670 
846 
 
1.07 (1.02-1.13) 
1.05 (0.96-1.16) 
 
0, 0.50 
56, 0.08 
NSAIDs use 
No 
Yes 
 
10 
2 
 
3298 
224 
 
1.06 (1.01-1.11) 
1.10 (0.94-1.30) 
 
46, 0.05 
53, 0.15 
 
8 
1 
2468 
48 
 
1.07 (1.02-1.13) 
1.00 (0.83-1.21) 
 
39, 0.12 
- 
Socioeconomic 
status 
No 
Yes 
 
 
9 
3 
 
 
3080 
442 
 
 
1.07 (1.01-1.12) 
1.08 (0.98-1.20) 
 
 
52, 0.03 
35, 0.22 
 
 
8 
1 
2468 
48 
 
 
1.07 (1.02-1.13) 
1.00 (0.83-1.21) 
 
 
39, 0.12 
- 
HT useh 
No 
Yes 
 
5 
6 
 
972 
2253 
 
1.10 (1.04-1.17) 
1.06 (0.99-1.14) 
 
0, 0.65 
67, 0.01 
 
4 
4 
 
724 
1495 
 
1.11 (1.03-1.19) 
1.06 (0.97-1.15) 
 
0, 0.68 
62, 0.05 
Physical activity 
No 
Yes 
 
8 
4 
 
2277 
1245 
 
1.09 (1.03-1.16) 
1.02 (0.97-1.08) 
 
42, 0.10 
15, 0.32 
 
6 
3 
 
1854 
662 
 
1.09 (1.04-1.14) 
1.00 (0.94-1.06) 
 
8, 0.37 
0, 0.64 
Alcohol use 
No 
Yes 
 
8 
4 
 
2078 
1444 
 
1.10 (1.05-1.15) 
1.02 (0.95-1.09) 
 
11, 0.34 
41, 0.16 
 
7 
2 
 
1902 
614 
 
1.08 (1.04-1.13) 
1.00 (0.94-1.06) 
 
2, 0.41 
0, 0.34 
f Studies reported no material change of risk estimate after early years of follow-up were excluded. 
g Fasting status was missing in Allin et al., 2009, Heikkila et al, 2009, Prizment et al., 2013 Zhang et al., 
2007, and Zeleniuch-Jacquotte et al. 2008; Blood sample was missing in Heikkila et al., 2009. 
h Excluded Gaudet et al., 2013, which was of non-HT users only.   
Note: Ph denotes P value for heterogeneity between studies in each subgroup analysis.  
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Figure legends 
Figure 1: Flowchart of systematic literature search of circulating C-reactive protein and breast cancer risk 
Figure 2: Summary relative risk per doubling of circulating CRP concentration and breast cancer risk 
A – Overall meta-analysis, B – Meta-analysis in postmenopausal women. 
Forest plots show the relative risk of breast cancer per doubling of CRP concentration in each study. Error 
bars indicate 95% confidence intervals. Size of the squares indicates the weight of each study in the 
random-effects meta-analysis. Diamonds indicate the summary relative risks.  
Figure 3: Non-linear dose-response meta-analysis of circulating CRP and breast cancer risk 
A – Scatter plot showing data from all studies, B – Overall non-linear dose-response curve, C – Scatter plot 
showing data from studies of postmenopausal women, D – Non-linear dose-response curve in 
postmenopausal women. 
Bubbles in the scatter plots represent the relative risk of breast cancer for the corresponding CRP 
concentration comparison as reported in the studies. Size of bubbles is proportional to the number of cases 
and non-cases included in the analysis. Crosses show the reference CRP concentrations of the studies. The 
middle line of the curves represents the relative risk of breast cancer compared with reference CRP 
concentration and the upper and lower side lines represent 95% confidence interval of the relative risk. 
Statistical analysis for nonlinearity was determined with the likelihood ratio test. 
 
 
 
 
 
 
1,025 publications identified until February 
2015 
    311 in PubMed 
    712 in Web of Science 
    2 from reference list of relevant reviews 
  
38 full-text publications retrieved and 
assessed for inclusion 
987 publications excluded on the basis of 
title and abstract 
22 publications excluded for not fulfilling 
the inclusion criteria 
 3 duplicate publications  
 2 reviews 
 1 meta-analysis 
11 did not report on the association of 
interest 
 4 hospital-based case-control studies 
 1 meeting abstract 
  
  
16 publications (15 studies) on circulating 
C-reactive protein and breast cancer risk 
12 studies included in the dose-response 
meta-analysis overall, 9 studies with 
results on postmenopausal women 
3 studies excluded in the dose-response 
meta-analysis because of insufficient 
data 
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